|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NNMT |
Gene summary for NNMT |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NNMT | Gene ID | 4837 |
| Gene name | nicotinamide N-methyltransferase | |
| Gene Alias | NNMT | |
| Cytomap | 11q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | P40261 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4837 | NNMT | GSM4909277 | Human | Breast | Precancer | 1.76e-04 | 6.98e-01 | 0.0177 |
| 4837 | NNMT | GSM4909285 | Human | Breast | IDC | 8.44e-15 | -3.98e-01 | 0.21 |
| 4837 | NNMT | GSM4909286 | Human | Breast | IDC | 6.26e-19 | -4.32e-01 | 0.1081 |
| 4837 | NNMT | GSM4909290 | Human | Breast | IDC | 1.30e-02 | -3.49e-01 | 0.2096 |
| 4837 | NNMT | GSM4909291 | Human | Breast | IDC | 1.23e-02 | -3.65e-01 | 0.1753 |
| 4837 | NNMT | GSM4909293 | Human | Breast | IDC | 3.43e-13 | -3.03e-01 | 0.1581 |
| 4837 | NNMT | GSM4909294 | Human | Breast | IDC | 1.58e-10 | -3.20e-01 | 0.2022 |
| 4837 | NNMT | GSM4909296 | Human | Breast | IDC | 5.87e-11 | -3.46e-01 | 0.1524 |
| 4837 | NNMT | GSM4909297 | Human | Breast | IDC | 5.33e-07 | -2.78e-01 | 0.1517 |
| 4837 | NNMT | GSM4909298 | Human | Breast | IDC | 1.08e-10 | -3.76e-01 | 0.1551 |
| 4837 | NNMT | GSM4909299 | Human | Breast | IDC | 2.06e-03 | 3.86e-01 | 0.035 |
| 4837 | NNMT | GSM4909301 | Human | Breast | IDC | 4.69e-19 | -4.26e-01 | 0.1577 |
| 4837 | NNMT | GSM4909304 | Human | Breast | IDC | 9.83e-13 | -3.89e-01 | 0.1636 |
| 4837 | NNMT | GSM4909307 | Human | Breast | IDC | 1.73e-07 | -3.24e-01 | 0.1569 |
| 4837 | NNMT | GSM4909308 | Human | Breast | IDC | 3.49e-10 | -4.18e-01 | 0.158 |
| 4837 | NNMT | GSM4909309 | Human | Breast | IDC | 1.06e-05 | 4.38e-01 | 0.0483 |
| 4837 | NNMT | GSM4909311 | Human | Breast | IDC | 1.19e-16 | -3.77e-01 | 0.1534 |
| 4837 | NNMT | GSM4909312 | Human | Breast | IDC | 5.96e-23 | -4.30e-01 | 0.1552 |
| 4837 | NNMT | GSM4909315 | Human | Breast | IDC | 6.54e-18 | -4.33e-01 | 0.21 |
| 4837 | NNMT | GSM4909316 | Human | Breast | IDC | 3.34e-04 | -4.35e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003106015 | Thyroid | ATC | regulation of histone methylation | 38/6293 | 69/18723 | 1.97e-04 | 1.31e-03 | 38 |
| GO:190129318 | Thyroid | ATC | nucleoside phosphate biosynthetic process | 110/6293 | 256/18723 | 1.06e-03 | 5.58e-03 | 110 |
| GO:000916518 | Thyroid | ATC | nucleotide biosynthetic process | 109/6293 | 254/18723 | 1.17e-03 | 6.15e-03 | 109 |
| GO:009031211 | Thyroid | ATC | positive regulation of protein deacetylation | 16/6293 | 25/18723 | 1.81e-03 | 8.90e-03 | 16 |
| GO:003496815 | Thyroid | ATC | histone lysine methylation | 54/6293 | 115/18723 | 2.00e-03 | 9.58e-03 | 54 |
| GO:004341412 | Thyroid | ATC | macromolecule methylation | 131/6293 | 316/18723 | 2.01e-03 | 9.60e-03 | 131 |
| GO:003225911 | Thyroid | ATC | methylation | 148/6293 | 364/18723 | 2.69e-03 | 1.23e-02 | 148 |
| GO:000941027 | Thyroid | ATC | response to xenobiotic stimulus | 184/6293 | 462/18723 | 2.70e-03 | 1.23e-02 | 184 |
| GO:000610913 | Thyroid | ATC | regulation of carbohydrate metabolic process | 78/6293 | 178/18723 | 2.81e-03 | 1.28e-02 | 78 |
| GO:004636411 | Thyroid | ATC | monosaccharide biosynthetic process | 39/6293 | 82/18723 | 6.04e-03 | 2.42e-02 | 39 |
| GO:00903116 | Thyroid | ATC | regulation of protein deacetylation | 25/6293 | 48/18723 | 6.27e-03 | 2.50e-02 | 25 |
| GO:001090612 | Thyroid | ATC | regulation of glucose metabolic process | 52/6293 | 119/18723 | 1.37e-02 | 4.77e-02 | 52 |
| GO:00193194 | Thyroid | ATC | hexose biosynthetic process | 36/6293 | 78/18723 | 1.43e-02 | 4.92e-02 | 36 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NNMT | deletion | Frame_Shift_Del | novel | c.175delN | p.Leu59Ter | p.L59* | P40261 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| NNMT | SNV | Missense_Mutation | rs141072720 | c.52N>T | p.Arg18Trp | p.R18W | P40261 | protein_coding | deleterious(0) | possibly_damaging(0.865) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| NNMT | SNV | Missense_Mutation | c.616N>C | p.Ile206Leu | p.I206L | P40261 | protein_coding | deleterious(0.01) | benign(0.08) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NNMT | SNV | Missense_Mutation | novel | c.703N>G | p.Phe235Val | p.F235V | P40261 | protein_coding | tolerated(0.27) | benign(0.445) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NNMT | SNV | Missense_Mutation | rs750805211 | c.697N>A | p.Glu233Lys | p.E233K | P40261 | protein_coding | tolerated(0.52) | benign(0.015) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NNMT | SNV | Missense_Mutation | c.141G>T | p.Lys47Asn | p.K47N | P40261 | protein_coding | deleterious(0.02) | benign(0.151) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NNMT | SNV | Missense_Mutation | novel | c.56N>C | p.Asp19Ala | p.D19A | P40261 | protein_coding | tolerated(0.5) | benign(0.006) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NNMT | SNV | Missense_Mutation | novel | c.187N>T | p.Gly63Cys | p.G63C | P40261 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NNMT | SNV | Missense_Mutation | c.133N>A | p.Leu45Ile | p.L45I | P40261 | protein_coding | deleterious(0.04) | benign(0.283) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NNMT | SNV | Missense_Mutation | c.416N>C | p.Leu139Pro | p.L139P | P40261 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4837 | NNMT | DRUGGABLE GENOME | NIACIN | NIACIN | ||
| 4837 | NNMT | DRUGGABLE GENOME | ARI-3037MO |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |